

EXHIBIT A

Name: Ceftriaxone Axetil
 Innovator: Glaxo
 Form: Tablet 125/250, 500 mg, Suspension 125/250 mg
 RM Suppliers: Accord, IpC, Ranbaxy, Aurubindo

MARKET DATA SUMMARY

1998 sales	1999 sales	Growth
Rs 494,350,375	Rs 560,022,765	13%

* Includes sodium Ceftriaxone injection

PRELIMINARY COSTING

Form: Tablet	Form: Suspension	Unit: 100% CDD	Unit: 10% CDD
	Rs 57/250 mg	Rs 63.20	Rs 47.62
	Rs 300/50 ml (125 mg)	NA	NA

PATENT STATUS

Patent	Remark	Patent expiry
Axetil	Isen derivatives	MY 12/31/2004
Amorphous form and Process	Amorphous form is the bioavailable form	MY 12/31/2004
Suspension	Composition patent: lipid coating for taste masking	IN 7/31/2005 US 1/20/2005 IN 7/31/2010 SA 8/23/2005
Tablet	Composition patent: thin film coating for rapid release	PP 18/18/2008 MY 4/30/2009 IN 10/26/2007

COMMENTS

Sodium Ceftriaxone used in the injection format is poorly absorbed when used orally. Ceftriaxone Axetil, an ester of Ceftriaxone, is a prodrug with good bioavailability. The commercial Ceftriaxone Axetil is in amorphous form. Composition patent for suspension can be circumvented by using non-lipid coating. First step is to look for supplier who can sell us non-infringing coated granules, if not available, develop formula. Composition patent for tablet is with thin film coating, can circumvent if we use capsule format or tablet without film coating, or tablet inside a capsule?